Cargando…

Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma

BACKGROUND: Our aim was to extend traditional parametric models used to extrapolate survival in cost-effectiveness analyses (CEAs) by integrating individual-level patient data (IPD) from a clinical trial with estimates from experts regarding long-term survival. This was illustrated using a case stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayers, Dieter, Cope, Shannon, Towle, Kevin, Mojebi, Ali, Marshall, Thomas, Dhanda, Devender
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569052/
https://www.ncbi.nlm.nih.gov/pubmed/36243687
http://dx.doi.org/10.1186/s12874-022-01745-z
_version_ 1784809779878690816
author Ayers, Dieter
Cope, Shannon
Towle, Kevin
Mojebi, Ali
Marshall, Thomas
Dhanda, Devender
author_facet Ayers, Dieter
Cope, Shannon
Towle, Kevin
Mojebi, Ali
Marshall, Thomas
Dhanda, Devender
author_sort Ayers, Dieter
collection PubMed
description BACKGROUND: Our aim was to extend traditional parametric models used to extrapolate survival in cost-effectiveness analyses (CEAs) by integrating individual-level patient data (IPD) from a clinical trial with estimates from experts regarding long-term survival. This was illustrated using a case study evaluating survival of patients with triple-class exposed relapsed/refractory multiple myeloma treated with the chimeric antigen receptor (CAR) T cell therapy idecabtagene vicleucel (ide-cel, bb2121) in KarMMa (a phase 2, single-arm trial). METHODS: The distribution of patients expected to be alive at 3, 5, and 10 years given the observed survival from KarMMa (13.3 months of follow-up) was elicited from 6 experts using the SHeffield ELicitation Framework. Quantities of interest were elicited from each expert individually, which informed the consensus elicitation including all experts. Estimates for each time point were assumed to follow a truncated normal distribution. These distributions were incorporated into survival models, which constrained the expected survival based on standard survival distributions informed by IPD from KarMMa. RESULTS: Models for ide-cel that combined KarMMa data with expert opinion were more consistent in terms of survival as well as mean survival at 10 years (survival point estimates under different parametric models were 29–33% at 3 years, 5–17% at 5 years, and 0–6% at 10 years) versus models with KarMMa data alone (11–39% at 3 years, 0–25% at 5 years, and 0–11% at 10 years). CONCLUSION: This case study demonstrates a transparent approach to integrate IPD from trials with expert opinion using traditional parametric distributions to ensure long-term survival extrapolations are clinically plausible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-022-01745-z.
format Online
Article
Text
id pubmed-9569052
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95690522022-10-16 Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma Ayers, Dieter Cope, Shannon Towle, Kevin Mojebi, Ali Marshall, Thomas Dhanda, Devender BMC Med Res Methodol Research BACKGROUND: Our aim was to extend traditional parametric models used to extrapolate survival in cost-effectiveness analyses (CEAs) by integrating individual-level patient data (IPD) from a clinical trial with estimates from experts regarding long-term survival. This was illustrated using a case study evaluating survival of patients with triple-class exposed relapsed/refractory multiple myeloma treated with the chimeric antigen receptor (CAR) T cell therapy idecabtagene vicleucel (ide-cel, bb2121) in KarMMa (a phase 2, single-arm trial). METHODS: The distribution of patients expected to be alive at 3, 5, and 10 years given the observed survival from KarMMa (13.3 months of follow-up) was elicited from 6 experts using the SHeffield ELicitation Framework. Quantities of interest were elicited from each expert individually, which informed the consensus elicitation including all experts. Estimates for each time point were assumed to follow a truncated normal distribution. These distributions were incorporated into survival models, which constrained the expected survival based on standard survival distributions informed by IPD from KarMMa. RESULTS: Models for ide-cel that combined KarMMa data with expert opinion were more consistent in terms of survival as well as mean survival at 10 years (survival point estimates under different parametric models were 29–33% at 3 years, 5–17% at 5 years, and 0–6% at 10 years) versus models with KarMMa data alone (11–39% at 3 years, 0–25% at 5 years, and 0–11% at 10 years). CONCLUSION: This case study demonstrates a transparent approach to integrate IPD from trials with expert opinion using traditional parametric distributions to ensure long-term survival extrapolations are clinically plausible. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-022-01745-z. BioMed Central 2022-10-15 /pmc/articles/PMC9569052/ /pubmed/36243687 http://dx.doi.org/10.1186/s12874-022-01745-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ayers, Dieter
Cope, Shannon
Towle, Kevin
Mojebi, Ali
Marshall, Thomas
Dhanda, Devender
Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma
title Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma
title_full Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma
title_fullStr Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma
title_full_unstemmed Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma
title_short Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma
title_sort structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of car t therapy for relapsed/ refractory multiple myeloma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569052/
https://www.ncbi.nlm.nih.gov/pubmed/36243687
http://dx.doi.org/10.1186/s12874-022-01745-z
work_keys_str_mv AT ayersdieter structuredexpertelicitationtoinformlongtermsurvivalextrapolationsusingalternativeparametricdistributionsacasestudyofcarttherapyforrelapsedrefractorymultiplemyeloma
AT copeshannon structuredexpertelicitationtoinformlongtermsurvivalextrapolationsusingalternativeparametricdistributionsacasestudyofcarttherapyforrelapsedrefractorymultiplemyeloma
AT towlekevin structuredexpertelicitationtoinformlongtermsurvivalextrapolationsusingalternativeparametricdistributionsacasestudyofcarttherapyforrelapsedrefractorymultiplemyeloma
AT mojebiali structuredexpertelicitationtoinformlongtermsurvivalextrapolationsusingalternativeparametricdistributionsacasestudyofcarttherapyforrelapsedrefractorymultiplemyeloma
AT marshallthomas structuredexpertelicitationtoinformlongtermsurvivalextrapolationsusingalternativeparametricdistributionsacasestudyofcarttherapyforrelapsedrefractorymultiplemyeloma
AT dhandadevender structuredexpertelicitationtoinformlongtermsurvivalextrapolationsusingalternativeparametricdistributionsacasestudyofcarttherapyforrelapsedrefractorymultiplemyeloma